Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533
Topic overview
COG study AREN0533 analyzed 251 children with favorable histology Wilms tumor and lung-only metastases, finding that 1q chromosomal gain is a stronger predictor of outcomes than pulmonary tumor burden. Treatment stratification based on rapid versus slow nodule response guided therapy intensity including lung radiation.
Key takeaways
- 1q chromosomal gain is a stronger predictor of outcomes than pulmonary tumor burden in stage IV favorable histology Wilms tumor patients.
- Rapid complete responders to DD-4A chemotherapy can avoid lung radiation while maintaining good outcomes regardless of initial nodule count.
- In slow incomplete responders treated with intensified therapy plus lung RT, initial pulmonary tumor burden does not significantly impact survival.
- Early nodule response assessment after 2 cycles of chemotherapy effectively stratifies treatment intensity in metastatic Wilms tumor.
- Size of lung metastases showed limited prognostic value compared to molecular markers like 1q gain in this cohort of 251 children.
Comments